New technologies boost safety for patients with cancer who need donated blood.
Then, in 2018, he developed myelodysplastic syndrome, another type of blood cancer that disrupts the production of blood cells, and needed a stem cell transplant. After that, he received seven transfusions of red blood cells, plus a few infusions of platelets.
It can be scary to see this big bag of blood coming in, says Sheldon, 55, who lives in Phoenix. He experienced some shaking and chills from the gamma globulin infusions at first, he says, but was ultimately able to tolerate most of the blood products he received and now feels confident hes on the road to recovery. Every day is a good day, he says.
A PLETHORA OF PRODUCTSBlood transfusions are routine in the treatment of patients with blood cancers. In fact, an estimated 15% of the 14 million or so blood units collected in the United States every year go to hematology and oncology patients. Although the safety of donated blood was a concern in the past, improvements in both the collection and testing of blood and its administration to patients have lessened the risks considerably. Among all patients treated with blood transfusions in 2017, the most recent year reported by the Food and Drug Administration (FDA), there were 44 deaths, down from 60 the previous year.
The blood supply has never been safer, says Dr. David Chow, medical director of the blood bank at Hackensack Meridian Health in New Jersey.
There are several types of transfusions that patients with blood cancers may need during thecourse of treatment. Patients who, like Sheldon, receive stem cell transplants are first given high doses of chemotherapy to deplete their own blood cells. Thats why after the transplant, they need transfusions of red blood cells, which carry oxygen; white blood cells to fight infections; and platelets to stem bleeding.
Even patients who dont need stem cell transplants can develop anemia during chemotherapy treatment. Oncologists cant prescribe drugs for anemia, such as Epogen (epoetin alfa), to patients with blood cancers because of the nature of those diseases. Epogen can stimulate the bone marrow to produce more red blood cells, but in patients with leukemia and lymphoma,the bone marrow is not functioning, says Dr. Qun Lu, a pathologist at Mayo Clinic in Phoenix.
For those patients, blood transfusions are considered supportive care, she adds: Even though they dont treat the cancer itself, they relieve symptoms of anemia, like extreme exhaustion and shortness of breath, and therefore are essential for helping patients fight the disease.
Some patients with blood cancers also may need infusions of plasma and/or albumin, both of which can be used to treat liver malfunctions that can occur during the course of therapy. Plasma contains clotting factors that help contain or prevent bleeding. Cryoprecipitate is derived from plasma and has specific coagulation factors for patients with specific deficiencies. Albumin, a protein thats abundant in blood and produced by the liver, is decreased in patients with liver disease or malnutrition and sometimes needs replacement.
AVERTING ADVERSE REACTIONSTransfusions of red blood cells generally take between two and four hours; plasma and platelet transfusions are generally faster. During the procedure, patients are monitored frequently to make sure there are no changes in vital signs such as temperature, heart rate and blood pressure and that no adverse reactions are occurring.
Some patients who receive transfusions develop reactions that manifest with flu-like symptoms, including chills, nausea and back pain, which can be treated by lowering the rate at which the blood is given and using over-the-counter remedies like Tylenol. However, sometimes these reactions can be severe and even fatal, so all transfusions require close monitoring and preparedness to intervene.
When patients receive regular blood transfusions, they can develop a condition called iron overload. Red blood cells contain iron, so each time a patient receives a red blood cell transfusion they are putting more iron into their body. Since this can be different for each person, a doctor will decide if a patient has iron overload and if treatment, such as iron chelation therapy, is needed. In addition, patients can develop antibodies against substances known as antigens on red blood cells or platelets from donors. That can make it more difficult to find compatible blood. To locate the proper match, before a transfusion, the patients blood is tested for both its aBO and Rh type and for the possible presence of antibodies.
Still, its important for patients who have developed antibodies against donated blood to alert their physicians of their history before every transfusion particularly if theyve moved to a new treatment center. Once these antibodies form, theyre considered lifelong; therefore, the patient is always at risk of having a reaction, says Dr. Kaaron Benson, director of the blood bank at Moffitt Cancer Center in Tampa, Florida. We may not know about it at our hospital if it happened somewhere else.
Some patients may need to have their blood specifically tested before they even begin their cancer treatments. For example, patients with multiple myeloma, a blood cancer that forms in a plasma cell, are often prescribed Darzalex (daratumumab), a drug thats effective at treating the cancer but also interferes with testing for blood compatibility. Those patients need to undergo special blood typing before starting Darzalex, in case they need donated blood down the road.
All donated blood components are carefully screened to ensure that donors do not unknowingly pass along viruses like HIV, hepatitis or West Nile. All platelet donations are also tested for bacterial contamination, though that testing isnt fail-safe. Thats because unlike red blood cell units, which can be refrigerated, platelets are stored at room temperature for up to five days. When you are storing platelets at room temperature, small amounts of bacteria can multiply into the millions and cause a severe infection, Lu says.
Last December, a 23-year-old woman being treated for acute lymphoblastic leukemia at The University of Texas MD Anderson Cancer Center in Houston died after receiving platelets that were contaminated with bacteria. The incident prompted the federal Centers for Medicare & Medicaid Services (CMS) to review safety procedures at the hospital. The agency reported that it found a number of safety shortcomings for example, nurses were not regularly monitoring the patients vital signs during the transfusion, nor had they done so for 18 other patients whose records the agency reviewed.
A spokesperson for MD Anderson said the hospital system transfuses 200,000 blood products each year, 75% of which are used in patients with hematological cancers. We have policies and procedures in place to protect our patients. However, in rare instances, severe reactions occur, the spokesperson said.
Since the CMS investigation, MD Anderson has reviewed all its safety procedures and retrained the nursing staff to practice more stringent patient monitoring. The hospitals lab is also establishing a hemovigilance unit for real-time monitoring of patients at risk for a transfusion reaction, the spokesperson said.
BANKING ON BETTER BLOODSome companies are developing technologies to make the blood supply even safer. In 2014, California-based Cerus won FDA approval for its product, Intercept, which combines a chemical compound with UVA to block the ability of viruses, bacteria or parasites in donated blood to replicate. The company has shown that the technology can inactivate more than 25 different pathogens.
More than 40 blood banks have started using Intercept-screened platelets routinely, including Mayo Clinic, even though it makes obtaining blood more costly, Lu says. It can be hundreds of thousands of dollars more in increased costs per year, she says. More than half the platelets we use are pathogen reduced, but wed like it to be 100%. Colorado-based Terumo BCT is developing Mirasol, a system that combines vitamin B2 (riboflavin) with ultraviolet light to inactivate pathogens and stray white blood cells in platelets, which can also cause reactions in some patients.
The product is approved in several countries and is being tested in clinical trials in the U.S.
Terumo hopes to apply the same technology to red blood cells, and in 2018, it started U.S. trials in patients to prove it is safe and effective.
Cerus is also working on moving its technology into the treatment of red blood cells. Many physicians welcome the idea of pretreating more than just platelets for pathogen reduction, because even though red blood cells can be refrigerated, theres a tiny chance that some bacteria can grow in cold temperatures.
The development process is behind for red blood cells, says Dr. Jeffrey McCullough, professor emeritus of laboratory medicine and pathology at the University of Minnesota in Minneapolis and a consultant to both Cerus and Terumo. But this research is moving ahead, and we expect over the next several years this will become the new paradigm for blood safety.
To lower the risks, some oncologists infuse just one unit of blood, then wait to see if the patient needs more, rather than ordering two or more units upfront. We used to think a two unit minimum of red blood cells for adults was important, Benson says. Now we have good studies showing we can lower our blood transfusion thresholds and reduce the number of units per transfusion episode, and that further reduces the risk to patients.
Another potential development on the horizon involves freeze-dried plasma, which was used in the military in World War II but fell out of favor because it raised the risk of transmitting hepatitis B. Now that its possible to test donated blood for viruses, freeze-drying plasma is making a comeback. In October 2018, the FDA approved a freeze-dried plasma product made in France for emergency use by the U.S. military.
Clinical trials are underway to determine whether freeze- dried plasma is safe to use in patients with a wide range of disorders, including cancer. The product is designed to be stored up to at least one year and then mixed with sterile water for any patient who needs a transfusion. This is something we could potentially use, particularly in the emergency setting or in remote areas, where patients sometimes face a delay waiting for plasma, which is usually frozen, to be prepared, Benson says.
The holy grail of blood transfusion is so-called artificial blood, a blood substitute, which could provide an alternative method for carrying oxygen through the body. Several companies and academic researchers have tried to develop artificial blood but had limited success. One product, Hemopure, was approved in South Africa but rejected for approval in the U.S. after advisers to the agency suggested further studies needed to be done to prove the products safety and efficacy. Overall, the human trials that have been done with artificial blood have reported an increased risk of heart attack and death.
So, for the foreseeable future, donated blood is the only option for patients with cancer who need transfusions.
For that reason, oncologists often urge family members and friends of patients to donate blood to help replenish the community supply.
Still, Chow says, its not necessary for patients to receive donated blood from someone they know. Patients often want their relatives to donate blood because they believe that blood is cleaner, but thats not the case. All blood donors are rigorously tested, Chow says. We want everyone to go out and donate blood. Even if the blood doesnt help that particular patient, it will help someone.
When blood is not needed urgently but might be anticipated after a major surgery, patients who start with normal blood counts can donate their own blood well in advance so that there is time for them to generate more blood, then have it stored and transfused back if needed because of blood loss after surgery.
For Sheldon, who still receives chemotherapy once a month, blood transfusions have become so routine that he no longer worries about the process. His advice to other patients? Dont be scared, he says. The doctors know what theyre doing, and theyre always testing, so you can have confidence that the blood theyre bringing in is the right match. Nevertheless, it is important for all patients receiving blood products to be aware of the risks and measures taken to reduce them.
- Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast - FierceBiotech - November 22nd, 2020
- Benefits of Hematopoietic Stem Cell Transplantation in Advanced Myelodysplastic Syndromes - Hematology Advisor - November 22nd, 2020
- YOUR HEALTH: Your body may already have the answer to knee pain - WQAD.com - November 22nd, 2020
- Providing CAR T-Cell Therapy for Patients With DLBCL During COVID-19 - Targeted Oncology - November 22nd, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization - OrthoSpineNews - November 22nd, 2020
- Stem Cell Therapy Market 2020 Trends, Market Share, Industry Size, Growth, Sales, Opportunities, Analysis and Forecast To 2026 - The Daily... - November 22nd, 2020
- Animal Stem Cell Therapy Market 2020 Impact of COVID-19 | Size, Share & Latest Trends, Analysis Report by Manufacturers, Application, Type and... - November 22nd, 2020
- Canine Stem Cell Therapy Market 2020 impact of COVID-19 on Industry Size, Share, Global Analysis, Development Status, Regional Trends, Opportunity... - November 22nd, 2020
- Stem Cell Therapy Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2026 - The Daily Philadelphian - November 22nd, 2020
- gift of life marrow registry announces new center for cell and gene therapy - The Boca Raton Tribune - November 22nd, 2020
- Global Canine Stem Cell Therapy Industry Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2026 - Royal Sutton News - November 22nd, 2020
- Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis? - DocWire News - November 22nd, 2020
- Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord in patients with Acute Myeloid Leukemia (AML) -... - November 22nd, 2020
- Impact Analysis of Covid-19 On Global Stem Cell Therapy Market Continues to Expand to Support Development and Top Players: Magellan, Medipost Co.,... - November 22nd, 2020
- Adrenoleukodystrophy Treatment Market: Rising awareness about rare diseases to drive the market - BioSpace - November 22nd, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - The Baytown Sun - November 16th, 2020
- Mesenchymal stem cells in the treatment of COVID-19-progress and challenges - DocWire News - November 16th, 2020
- The Animal Stem Cell Therapy market to fill the growth bill in the next decade - The Think Curiouser - November 16th, 2020
- Malaysia Animal Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2027 - Eurowire - November 16th, 2020
- Addenbrooke's becomes first regional centre to offer CAR-T cell treatment for cancer patients - Cambridge Network - November 16th, 2020
- Stem Cell Therapy Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - The Daily Philadelphian - November 16th, 2020
- Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review - DocWire News - November 16th, 2020
- Global cryotherapy market size to reach USD 6.72 billion by 2026 - GlobeNewswire - November 16th, 2020
- Stem Cell Therapy Market 2020 Future Growth Factors and Opportunities by 2025 - PRnews Leader - November 16th, 2020
- Stem Cell Therapy Market 2020 Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional and Global Industry Forecast To 2025 - PRnews... - November 16th, 2020
- BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for... - November 16th, 2020
- Stem Cell Banking Market To See Massive Growth By 2027| Cryo-Save AG, StemCyte India Therapeutics, SMART CELLS PLUS, Vita 34, LifeCell - PRnews Leader - November 9th, 2020
- It's time for Kentucky to talk to expectant parents about benefits of cord blood banking - Courier Journal - November 9th, 2020
- Global Stem Cell Therapy Market 2020 : Analysis of Expansion Strategy on Industry, Growth Factors and Expected CAGR Of Top Leaders, Upcoming... - November 9th, 2020
- Stem Cell Banking Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2028|Esperite, Caladrius Biosciences, Via Cord, CBR... - November 9th, 2020
- Doctors Consider Convalescent T Cell Therapy for COVID-19 - The Scientist - November 7th, 2020
- Canine Stem Cell Therapy Market Analysis, Latest Trends and Regional Growth Forecast by Types and Applications 2020 - TechnoWeekly - November 7th, 2020
- Cancer Stem Cell Therapy Market: Industry Trends and Developments 2020-2025 - Zenit News - November 7th, 2020
- Stem Cell Therapy Market 2020: Size, Professional Survey, and Forecast to 2025 - PRnews Leader - November 7th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 7th, 2020
- Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma - Curetoday.com - November 7th, 2020
- Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease - GlobeNewswire - November 7th, 2020
- Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American... - November 7th, 2020
- bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition -... - November 7th, 2020
- Voters approve stem cell research bonds, but other health care measures defeated - State of Reform - State of Reform - November 5th, 2020
- Stem cells key to ALS therapy - Agoura Hills Acorn - November 5th, 2020
- Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. - UroToday - November 5th, 2020
- New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation - DocWire News - November 5th, 2020
- Emerging Trends in Global Canine Stem Cell Therapy Market Report 2020,Deeply Analyzes Share, Types, Applications and Future Demands by Key Players-... - November 5th, 2020
- Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive - November 5th, 2020
- Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader - November 5th, 2020
- Stem Cell Therapy Market Insights Global Analysis and Forecast by (2020 2027) - The Think Curiouser - November 5th, 2020
- Animal Stem Cell Therapy Consumption Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Eurowire - November 5th, 2020
- Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case - FiercePharma - November 5th, 2020
- Stem Cell Therapy Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of... - November 5th, 2020
- Animal Stem Cell Therapy Market Future Demand Analysis with Forecast 2020 to 2027 - PRnews Leader - November 5th, 2020
- Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX... - November 5th, 2020
- Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of... - November 5th, 2020
- CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology... - November 5th, 2020
- Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting - Business Wire - November 5th, 2020
- XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma - BioSpace - November 5th, 2020
- Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |... - November 5th, 2020
- Animal Stem Cell Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions -... - November 5th, 2020
- Covid-19 Impact On Animal Stem Cell Therapy Market Analysis, Trends, Share, Size, Consumption 2020 2026 | MediVet Biologic, VETSTEM BIOPHARMA, J-ARM,... - November 5th, 2020
- Stem Cell Therapy for Autism: Effects & Costs in 2020 - November 1st, 2020
- aHSCT Gets a Boost in US With NMSS Recommendations - Multiple Sclerosis News Today - November 1st, 2020
- Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View - November 1st, 2020
- How pain changes your brain - News - The University of Sydney - November 1st, 2020
- Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? - SurvivorNet - October 31st, 2020
- Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 - Aerospace Journal - October 31st, 2020
- Animal Stem Cell Therapy Market 2020 Size, Share, Trends Analysis Report by Application, Region (North America, South America, Asia, and Europe) and... - October 31st, 2020
- Canine Stem Cell Therapy Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2026 - PRnews Leader - October 31st, 2020
- What Are the Treatment Options When Lymphoma Returns? - SurvivorNet - October 31st, 2020
- Philadelphia Based Company Wants to Bring Back the Dead With Stem Cells - Gilmore Health News - October 31st, 2020
- Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesnt Work - SurvivorNet - October 31st, 2020
- Stem Cell Therapy Market | Growth Strategies Adopted By Top Key Players,Future Trends ,Application Worldwide And Assessment To 2026 - PRnews Leader - October 31st, 2020
- Here's What Happens When Lab-Grown Mini-Lungs Are Exposed to SARS-CoV-2 - ScienceAlert - October 31st, 2020
- Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant... - October 31st, 2020
- Stem Cell Therapy Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader - October 31st, 2020
- Innovations in the Rheumatoid Arthritis Stem Cell Therapy Field Likely to Aid the Growth of the Rheumatoid Arthritis Stem Cell Therapy Market 2018 to... - October 31st, 2020
- Stem Cell Umbilical Cord Blood Market to Enable the Stakeholders to Capitalize on the Prevailing Industry Opportunities with Investment Analysis By... - October 31st, 2020
- Cynata looking to revolutionise stem cell therapy - The West Australian - October 28th, 2020
- Exclusive: "Ending Disease" Documentary Explores How Stem Cell Therapy Aims to Cure the Incurable - Prevention.com - October 28th, 2020
- Stem Cell Therapy Industry Market Size, Global Analytical Overview, Key Players, Regional Demand, Trends and Forecast To 2026 - Aerospace Journal - October 28th, 2020
- Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation - PRNewswire - October 28th, 2020